Related Experiment Video
Updated: Aug 13, 2026
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Some problems of therapeutic trials in hypertension
Insights
Standardizing hypertension trials requires clear protocols. Key elements include defining hypertension levels, measurement conditions, and specific endpoints for accurate therapeutic assessments.
Area of Science:
- Cardiovascular Medicine
- Clinical Trial Design
- Hypertension Research
Background:
- Controlled therapeutic trials in hypertension are crucial for evaluating new treatments.
- Existing protocols may lack standardization, leading to variability in results.
- A comprehensive protocol ensures reproducibility and comparability of trial data.
Purpose of the Study:
- To outline essential components for a scientific protocol in hypertension therapeutic trials.
- To provide recommendations for standardizing blood pressure measurement and endpoint definitions.
- To enhance the rigor and reliability of hypertension clinical research.
Main Methods:
- The study recommends specific inclusions for hypertension trial protocols.
- These include defining hypertension criteria (systolic/diastolic, age, sex).
- Recommendations cover measurement techniques (cuff size, arm, posture, conditions, timing) and baseline establishment.
Main Results:
- The abstract details ten key areas for protocol development.
- These range from defining hypertension levels and types to specifying measurement procedures.
- It also emphasizes clear endpoint definitions for therapeutic success.
Conclusions:
- A standardized scientific protocol is vital for controlled hypertension therapeutic trials.
- Adherence to these recommendations will improve data quality and trial validity.
- This standardization facilitates more reliable comparisons of treatment efficacy.
Abstract:
It is strongly recommended that a scientific protocol for controlled therapeutic trials in hypertension should include, inter alia, the following: 1. A definition of the level(s) of blood pressure which indicate hypertension (systolic and/or diastolic), preferably related to age and sex. 2. The criteria for defining the type of hypertension (e.g., essential, renovascular, etc.). 3. A statement relative to which diastolic level is to be recorded: phase IV ("muffling") and/or phase V ("disappearance"). 4. Information on the sizes of sphygmomanometer cuffs to be used. 5. A statement of which arm is to be used (throughout the study). 6. A statement of postures in which blood pressure is to be measured (supine, sitting, standing). 7. Information on the conditions under which pressures are to be recorded (e.g., "casual," "near-basal," etc.) and the duration of rest before recording. 8. Details of the times of day at which measurements are to be taken.9. A statement on the method of establishing baseline readings (e.g., mean of three successive readings) and the acceptable degree of variability (e.g., +/- 10 mm Hg). 10. A definition of "endpoints" (e.g., diastolic pressure less than upper limit of normal; reduction in diastolic pressure greater than 10 mm Hg).
More Related Videos
Related Concept Videos
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
01:23Hypertension V: Nursing Management